Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$16,754 Mln
P/E Ratio
41.28
P/B Ratio
13.83
Industry P/E
--
Debt to Equity
0.07
ROE
0.43 %
ROCE
24.29 %
Div. Yield
0 %
Book Value
16.36
EPS
5.65
CFO
$468.09 Mln
EBITDA
$492.14 Mln
Net Profit
$68.66 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Insulet (PODD)
| -0.21 | -2.91 | -6.02 | 55.75 | 1.47 | 4.79 | 23.88 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Midcap 400
| -8.90 | -3.61 | -13.39 | -2.06 | 3.20 | 13.18 | 6.31 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Insulet (PODD)
| 20.14 | -26.30 | 10.64 | 4.08 | 49.32 | 115.83 | 14.87 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 203.58 | 56,453.62 | 33.1 | 6.76 | |
| 75.48 | 40,534.25 | 29.57 | 50.15 | |
| 436.41 | 32,954.51 | 38.15 | 57.66 | |
| 226.03 | 34,179.18 | 48.63 | 13.63 |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin... delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Address: 100 Nagog Park, Acton, MA, United States, 01720 Read more
President, CEO & Director
Dr. James R. Hollingshead Ph.D.
President, CEO & Director
Dr. James R. Hollingshead Ph.D.
Headquarters
Acton, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Insulet Corporation (PODD) stood at $ 3,088 Mln as on 31-Dec-24
The share price of Insulet Corporation (PODD) is $260.53 (NASDAQ) as of 24-Apr-2025 12:41 EDT. Insulet Corporation (PODD) has given a return of 1.47% in the last 3 years.
Insulet Corporation (PODD) has a market capitalisation of $ 16,754 Mln as on 22-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/E ratio of Insulet Corporation (PODD) is 41.28 times as on 22-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Insulet Corporation (PODD) and enter the required number of quantities and click on buy to purchase the shares of Insulet Corporation (PODD).
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Address: 100 Nagog Park, Acton, MA, United States, 01720
The CEO & director of Dr. James R. Hollingshead Ph.D.. is Insulet Corporation (PODD), and CFO & Sr. VP is Dr. James R. Hollingshead Ph.D..
There is no promoter pledging in Insulet Corporation (PODD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
5,754
|
|
|
4,171
|
|
|
3,590
|
|
|
3,274
|
| Insulet Corporation (PODD) | Ratios |
|---|---|
|
Return on equity(%)
|
43.03
|
|
Operating margin(%)
|
16.55
|
|
Net Margin(%)
|
20.19
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Insulet Corporation (PODD) was $418 Mln.
$14.04
(
